Your browser doesn't support javascript.
Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers.
Hyun, JongHoon; Park, Yongjung; Song, Young Goo; Han, Sang Hoon; Park, Soon Young; Kim, Sin Hye; Park, Ji Su; Jeon, So Young; Lee, Hye Sun; Lee, Kyoung Hwa.
  • Hyun J; Division of Infectious Diseases, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
  • Park Y; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Song YG; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Han SH; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Park SY; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Kim SH; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Park JS; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Jeon SY; Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Korea.
  • Lee HS; Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Korea. hslee1@yuhs.ac.
  • Lee KH; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. khlee0309@yuhs.ac.
Yonsei Med J ; 63(12): 1078-1087, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2141689
ABSTRACT

PURPOSE:

The association between reactogenicity and immunogenicity of the ChAdOx1 nCOV-19 is controversial. We aimed to evaluate this association among South Korean healthcare workers (HCWs). MATERIALS AND

METHODS:

Participants received two doses of the ChAdOx1vaccine 12 weeks apart. Blood samples were tested for anti-severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein receptor binding domain antibodies about 2 months after the first and second doses using the Elecsys Anti-SARS-CoV-2 S assay kits. Adverse events were noted using an online self-reporting questionnaire.

RESULTS:

Among the 232 HCWs, pain (85.78% after the first dose vs. 58.62% after the second dose, p<0.001) was the most prominent local reaction, and myalgia or fatigue (84.05% vs. 53.02%, p<0.001) was the most prominent systemic reaction. The frequency of all adverse events was significantly reduced after the second dose. After the first dose, the anti-SARS-CoV-2 S showed significantly higher titer in the group with swelling, itching, fever, and nausea. Also, the anti-SARS-CoV-2 S titer significantly increased as the grade of fever (p=0.007) and duration of fever (p=0.026) increased; however, there was no significant correlation between immunogenicity and adverse event after the second dose. The group with pain after the first dose showed a greater increase in the anti-SARS-CoV-2 S difference between the second and first doses compared to the group without pain (542.2 U/mL vs. 363.8 U/mL, p=0.037).

CONCLUSION:

The frequency of adverse events occurring after the first dose of the ChAdOx1 was significantly reduced after the second dose. Interestingly, the elevation of anti-SARS-CoV-2 S titer was significantly increased in the group with pain after the first dose.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Observational study Topics: Vaccines Limits: Humans Country/Region as subject: Asia Language: English Journal: Yonsei Med J Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Observational study Topics: Vaccines Limits: Humans Country/Region as subject: Asia Language: English Journal: Yonsei Med J Year: 2022 Document Type: Article